Navigation Links
First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers

Two compounds that zero in on cancer cells spreading throughout the body, while ignoring primary tumor cells, could someday give doctors a whole new weapon in the fight against tough-to-treat metastatic disease, according to Weill Medical College of Cornell University researchers.

The compounds, called synthetic migrastatin analogues, prevented 91 to 99 percent of metastatic breast cancer cells in mice, and are the first to target only metastatic cells.

"They're unbelievably effective, and in vitro study suggests they'll work just as well at inhibiting the migration of prostate and colon cancer cells," said senior researcher Dr. Xin-Yun Huang, Professor of Physiology and Biophysics at Weill Cornell Medical College in New York City.

The findings have just been published in Proceedings of the National Academy of Sciences.

For decades, doctors have fought cancer by using surgery, chemotherapy, or radiation to excise or shrink the primary tumor.

"However, in too many cases it's simply impossible to completely remove the tumor," Dr. Huang explained. "So recently the idea of targeting cell migration -- metastasis -- has become an alternative strategy that's gained a lot of interest among researchers."

If compounds could be found that slowed or halted cancer spread, doctors could gain valuable time in shrinking the primary tumor. "If we had the luxury of time, we could treat that primary tumor at lower doses, too, with fewer side effects for the patient," Dr. Huang said.

Until now, agents that specifically target metastatic cells have remained elusive. However, a new avenue of research opened up when Dr. Huang's team noticed that the Streptomyces bacterium -- the bug that gives us the antibiotic streptomycin -- also produces a natural compound called migrastatin, which appears to inhibit cell migration.

Natural migrastatin's effect is relatively weak, but Dr. Huang suspected the molecule might be manipulated in to something more potent. In collaboration with the laboratory of Dr. Samuel Danishefsky at the Memorial Sloan-Kettering Cancer Center, the team went to work creating what's called a "synthetic analogue."

"Starting with the basic migrastatin molecule, we cut a piece there, add a piece here," he explained, "and what we ended up with were two compounds -- core macroketone and core macrolactam -- that are about 1,000 times more powerful at inhibiting cancer cell migration."

In fact, in a mouse model, the analogues were between 91 to 99 percent effective in stopping the spread of breast cancer cells, the researchers report. Cell culture studies suggest they can reproduce that success in a wide range of other cancers, too.

"What's unique about these analogues is that they do all this without affecting primary tumor cells, or their blood supply," Dr. Huang said. "To our knowledge, that's a real first."

Exact mechanisms remain unclear.

"Obviously, these compounds are targeting some step in the cell-migration process," Dr. Huang said. The activity of a migration-linked protein called Rac appears to be much reduced in cancer cells affected by the analogues, and the researchers also noticed that malignant cells failed to grow tiny "antennas," called lamellipodia, another crucial step in the migration process.

"Therefore, the migrastatin analogues must be working on something upstream of those two important steps," Dr. Huang said.

Dr. HuangÕs next important step is moving these analogues into clinical trials.

"We're trying right now to get a company interested in this, especially because the mice used in our trial seemed to experience minimal toxicity -- a good sign that patients might tolerate these compounds, too," Dr. Huang said.

"It's all very exciting," he said. "Metastatic disease is such a tough problem, and these compounds could provide patients with a brand new kind of hope."

The research was funded by grants from the National Institutes of Health.

Co-researchers included Ms. Dandan Shan (first author), Mr. Lin Chen, and Dr. Xiaojing Ma, of Weill Cornell Medical College; and Dr. Jon T. Njardarson, Dr. Christoph Gaul, and Dr. Samuel Danishefsky, of Memorial Sloan-Kettering Cancer Center, New York.


'"/>

Source:Cornell University


Related biology news :

1. First-ever genomic test predicts which lung cancer patients need chemotherapy to live
2. Compounds in plastic packaging act as environmental estrogens altering breast genes
3. Novel Enzyme Shows Potential As An Anti-HIV Target
4. Potential Drug Target For Treating Cocaine Abuse Found
5. Affymetrix and ParAllele Launch Industrys Most Comprehensive Product Line for Targeted Genotyping
6. Targeting a key enzyme with gene therapy reversed course of Alzheimers disease in mouse models
7. New Therapeutic Target Identified In Inherited Brain Tumor Disorder
8. Targeted drug delivery achieved with nanoparticle-aptamer bioconjugates
9. Targeted virus compels cancer cells to eat themselves
10. Best of both worlds -- Targeting a single gene could inhibit bone decay and stimulate bone growth
11. Targeting tumors the natural way
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/22/2016)... Jan. 22, 2016 ... of the "Global Biometrics Market in ... offering. --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ) ... "Global Biometrics Market in Retail Sector 2016-2020" ... --> Research and Markets ( http://www.researchandmarkets.com/research/p74whf/global_biometrics ...
(Date:1/20/2016)... A market that just keeps on growing. ... explosion in genomics knowledge. Learn all about it in ... of dynamic trends are pushing market growth and company ... pharmacogenomics - pathogen evolution - next generation sequencing - ... understanding of the role of genetic material in Disease ...
(Date:1/20/2016)... Calif. , Jan. 20, 2016  Synaptics ... of human interface solutions, today announced sampling of ... solution for wearables and small screen applications including ... as printers. Supporting round and rectangular shapes, as ... offers excellent performance with moisture on screen, while ...
Breaking Biology News(10 mins):
(Date:2/5/2016)... , Feb. 5, 2016  In the pharmaceutical ... for a host of launch activities including the identification ... this launch activity is especially high in the oncology ... Best Practices and the Role of Medical Affairs ... companies focused on oncology therapies find better ways to ...
(Date:2/5/2016)... , February 5, 2016 Amarantus ... biotechnology company focused on developing products for Regenerative Medicine, ... Rare Pediatric Disease Designation (RPDD) from the US Food ... with MANF. MANF was previously granted orphan drug designation ... --> Amarantus BioScience Holdings, Inc. (OTCQB: ...
(Date:2/4/2016)... ... February 04, 2016 , ... Morf Media Inc ... an interactive FDA compliance training course, Writing Effective SOPs ... accredited interactive course on Morf Playbook—now conveniently available on smartphones and PCs--provides step ...
(Date:2/4/2016)... 2016  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), ... Edward Lanphier , Sangamo,s president and chief executive ... Sangamo,s ZFP Therapeutic ® development programs and an ... ET on Thursday, February 11, 2016, at the Leerink ... conference is being held in New York ...
Breaking Biology Technology: